The U.S. Food and Drug Administration (FDA) has cleared the IND for Eilean Therapeutics’ lomonitinib (ZE46-0134), allowing the company to proceed with a Phase 1 clinical trial in FLT3 mutated relapsed/refractory (R/R) AML.    While the Phase 1 study has already been initiated in Australia, clearance from the FDA will allow the trial to be initiated in the US.   Lomonitinib is a highly potent and selective pan-FLT3/IRAK4 inhibitor that targets clinically relevant FLT3 mutations and putative e...